HC Wainwright reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Monday morning, AnalystRatings.com reports. They currently have a $26.00 target price on the stock.

“Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030.”,” HC Wainwright’s analyst commented.

VYGR has been the subject of a number of other research reports. Morgan Stanley boosted their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the stock an equal weight rating in a research report on Friday, July 12th. BidaskClub downgraded Voyager Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 7th. Nomura boosted their target price on Voyager Therapeutics from $26.00 to $37.00 and gave the stock a buy rating in a research report on Thursday, June 20th. Finally, Wedbush boosted their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the stock an outperform rating in a research report on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $27.50.

Shares of VYGR opened at $20.62 on Monday. The stock has a fifty day moving average price of $24.00 and a two-hundred day moving average price of $20.68. Voyager Therapeutics has a 52-week low of $7.76 and a 52-week high of $28.79. The company has a market cap of $791.41 million, a price-to-earnings ratio of -7.50 and a beta of 2.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $1.17. The company had revenue of $46.09 million during the quarter, compared to the consensus estimate of $5.25 million. Voyager Therapeutics had a negative return on equity of 82.98% and a negative net margin of 106.23%. On average, sell-side analysts forecast that Voyager Therapeutics will post -2.67 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in VYGR. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 15.8% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock valued at $252,000 after purchasing an additional 1,794 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Voyager Therapeutics by 1.0% in the first quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock valued at $890,000 after purchasing an additional 469 shares during the last quarter. Spark Investment Management LLC increased its holdings in Voyager Therapeutics by 18.5% in the first quarter. Spark Investment Management LLC now owns 146,200 shares of the company’s stock valued at $2,798,000 after purchasing an additional 22,800 shares during the last quarter. Bank of America Corp DE increased its holdings in Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after purchasing an additional 7,217 shares during the last quarter. Finally, Bailard Inc. bought a new stake in Voyager Therapeutics in the second quarter valued at about $1,116,000. Institutional investors own 73.92% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

See Also: What is an investor looking for in an SEC filing?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.